Proteon Therapeutics is a biopharmaceutical company developing pharmaceuticals for patients with renal and vascular diseases.
Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 10, 2021 | Post-IPO Equity | €21M | 5 |
Aqua Spark
Nutreco
|
— | Detail |
| Jul 25, 2019 | Grant | — | 1 |
|
— | Detail |
| Jun 22, 2017 | Post-IPO Equity | $22M | 1 |
|
— | Detail |
| Nov 25, 2014 | IPO | $70.30M | — | — | — | Detail |
| May 16, 2014 | Series D | $45M | 13 |
Abingworth
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Aqua Spark
|
Yes | Post-IPO Equity |
|
|
Yes | Post-IPO Equity |
Nutreco
|
Yes | Post-IPO Equity |
|
|
Yes | Grant |
|
|
Yes | Post-IPO Equity |
Abingworth
|
Yes | Series D |
Montis Capital
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
|
|
— | Series D |
Inbio Ventures
|
— | Series D |
Proteon Therapeutics has acquired 1 organizations. Their most recent acquisition was Protara Therapeutics on Sep 23, 2019. They acquired Protara Therapeutics for 0.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Sep 23, 2019
Protara Therapeutics
|
Biotechnology | merge | — | Detail |